SiBone (NASDAQ:SIBN) Issues Earnings Results

SiBone (NASDAQ:SIBN) announced its earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05, FiscalAI reports. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. The company had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million.

Here are the key takeaways from SiBone’s conference call:

• Third-quarter revenue rose 14.5% to $55.7 million, while U.S. procedure volume increased 19.5% and active physicians grew 16% to approximately 1,770. Management cited broad-based demand across surgeons, interventional spine physicians, and trauma procedures.
• The early alpha launch of iFuse Granite Onyx is generating demand ahead of the comparable Granite launch, including adoption by existing Granite users and new physicians. Onyx expands the company’s estimated addressable market to more than 650,000 procedures and approximately $5 billion.
• New spinal-fusion DRGs became effective October 1 and may increase hospital reimbursement by up to $50,000 for qualifying cases, supporting Granite adoption and potentially Onyx utilization. SI-BONE has also applied for an Onyx NTAP, which could take effect in October 2027 if approved.
• Profitability and cash generation improved, with adjusted EBITDA up 32.4% to $3.0 million, a 5.5% margin, and year-to-date operating cash flow of $4.4 million. The company lowered its expected 2026 operating-expense growth to 10.5% from 12% while reaffirming full-year revenue guidance of $231 million to $233 million.
• Average selling price declined because of a higher mix of lower-priced INTRA procedures in ASC and office settings and more two-implant Granite cases. Management expects modest gross-margin pressure in 2027 as it adds Onyx surgical capacity and launches additional products, although it continues to target long-term operating leverage.

SiBone Stock Down 4.8%

SIBN stock opened at $20.22 on Tuesday. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm’s 50-day simple moving average is $19.42 and its 200 day simple moving average is $16.45. The stock has a market cap of $896.76 million, a PE ratio of -59.47 and a beta of 0.66. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $22.95.

Trending Headlines about SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results exceeded estimates. SiBone reported a loss of $0.08 per share, narrower than the $0.13 consensus loss. Revenue increased 14.5% year over year to $55.7 million, slightly above the $55.3 million estimate. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume rose approximately 20%, adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow reached $5.9 million, up 154.4% year over year. The company ended the quarter with $146.3 million in cash. SI-BONE Third-Quarter 2026 Results
• Positive Sentiment: Management reaffirmed its 2026 revenue guidance. SiBone also highlighted FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to approximately $50,000 for qualifying procedures, potentially supporting future adoption. SI-BONE Guidance and Product Update
• Neutral Sentiment: Losses remain. Net loss improved 20.7% to $3.6 million, but SiBone still has a negative net margin and is expected to report a full-year loss.
• Negative Sentiment: Insider selling may pressure sentiment. SVP Michael Pisetsky sold 29,665 shares for about $655,893, reducing his ownership by 15.28%. Insider Anshul Maheshwari sold 3,738 shares for approximately $84,105 and reduced his position by 1.71%. Both retained substantial holdings, but the transactions occurred near the stock’s 52-week high. SiBone Insider Sales

Insider Activity at SiBone

In related news, SVP Michael A. Pisetsky sold 29,665 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $22.11, for a total transaction of $655,893.15. Following the completion of the sale, the senior vice president directly owned 164,444 shares in the company, valued at approximately $3,635,856.84. This trade represents a 15.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey Dunn sold 20,000 shares of SiBone stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $18.47, for a total value of $369,400.00. Following the completion of the transaction, the director directly owned 16,057 shares in the company, valued at $296,572.79. This represents a 55.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 238,371 shares of company stock worth $4,738,916. 4.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently commented on the company. TD Cowen boosted their price target on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Citigroup restated a “market outperform” rating on shares of SiBone in a report on Tuesday. Needham & Company LLC cut their target price on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Truist Financial upped their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.33.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.